Niclosamide was shown to decrease survival and self-renewal capacity of CD34+ CML LSCs, while ex vivo exposure of CML CD34+ cells decreased long-term engraftment in mice. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.